MORF News and Press, Morphic Holding Inc. From 01/14/21

The following slide deck was published by Morphic Holding, Inc. in conjunction with this event. For further details see: Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow

WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the expansion of its research and development col...

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39 th Annual J.P. Morgan Hea...

WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors. Dr. Edwards is a veteran leader in the drug development indu...

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management ...

Morphic (MORF): Q3 GAAP EPS of $0.17 beats by $0.71.Revenue of $25.76M (+353.5% Y/Y) beats by $13.46M.Press Release For further details see: Morphic EPS beats by $0.71, beats on revenue

Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021 Presented d ata at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057 Received $20 million from AbbVie exercising option to αv&#...

- Data validat e physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α 4 β 7 integrin - -MORF-057, inhibitor of α 4 β 7 integr...

First o rally available integrin inhibitor from MInT Platform to enter the clinic MORF-057, inhibitor o f α 4 β 7 integrin , in development to treat i nflammatory bowel disease Phase 1 pr...

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Nex...